Inactive Instrument

InterMune Inc Share Price

Equities

US45884X1037

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2014	CHUGAI PHARMACEUTICAL : Roche's $8 billion InterMune buy not a signal for more big deals	RE
2014	Roche : rules out mega deals, open to smaller ones - paper	RE

on all our subscriptions*

Take advantage of the offer

* See conditions on site

Latest news about InterMune Inc

CHUGAI PHARMACEUTICAL : Roche's $8 billion InterMune buy not a signal for more big deals	16/14/16	RE
Roche : rules out mega deals, open to smaller ones - paper	04/14/04	RE
Biogen Idec : InterMune drug may offer big upside to Roche if aimed at liver	28/14/28	RE
Burger King Worldwide : S&P 500 sets record high but fails to hold 2,000 mark	26/14/26	RE
CHUGAI PHARMACEUTICAL : Roche to buy U.S. biotech firm InterMune for $8.3 billion	25/14/25	RE
Horizon Pharma Inc : With eye on tax rates, Horizon Pharma buys Ireland's Vidara	19/14/19	RE
NVIDIA Corporation : SAC insider-trading probe could last years	07/13/07	RE
Weight Watchers International, Inc. : SAC Capital up 4 percent this year as probe continues	20/13/20	RE
Morgan Stanley : Cohen's SAC to pay $616 million in SEC insider trade settlement	16/13/16	RE
InterMune, Inc. : Blackstone seen sticking with SAC despite insider trading probe	28/12/28	RE
Weight Watchers International, Inc. : SAC Capital's top consumer trader draws U.S. scrutiny	19/12/19	RE
Elan Corporation, plc : Exclusive: U.S. authorities probe SAC for Weight Watchers - sources	08/12/08	RE
InterMune, Inc. : InterMune posts lower-than-expected revenue	23/12/23	RE

Press releases InterMune Inc

InterMune : Announces Effective Date of Make Whole Fundamental Change and Offer to Purchase to Holders of 2.50% Senior Convertible Notes Due 2018	02/14/02	PU
InterMune : Announces Anticipated Fundamental Change for 5.00% Convertible Senior Notes Due 2015	05/14/05	PR
InterMune : Stockholders Encouraged to Contact Securities Law Firm about Takeover	28/14/28	PR
InterMune : Ryan & Maniskas, LLP : Announces Investigation of InterMune, Inc.	26/14/26	PR
InterMune : Newman Ferrara LLP : Announces Investigation of InterMune, Inc.	25/14/25	BU

More press releases

News in other languages on InterMune Inc

Wall Street finit dans le vert, le S&P passe un cap	26/14/26
Burger King Worldwide : Wall Street ouvre en hausse sur un nouveau record du S&P	25/14/25
Apple : USA-Les valeurs à suivre à Wall Street	25/14/25
CHUGAI PHARMACEUTICAL : Roche achète l'américain InterMune pour 8,3 milliards de dollars	25/14/25
Roche va racheter l'américain InterMune pour $8,3 mds	25/14/25

Managers and Directors - InterMune Inc

Managers	Title	Age	Since
Edward Harrington CEO	Chief Executive Officer	-	-
Marianne T. Armstrong CTO	Chief Tech/Sci/R&D Officer	69	01/02/01
Carla Fiankan LAW	General Counsel	-	01/11/01

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+29.03%	48.16B
IQVIA HOLDINGS INC.	-0.10%	41.73B
LONZA GROUP AG	+43.45%	41.03B
CELLTRION, INC.	-5.26%	28.77B
ICON PUBLIC LIMITED COMPANY	+11.48%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.96B
BIO-TECHNE CORPORATION	+9.06%	12.92B
MEDPACE HOLDINGS, INC.	+30.01%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.77B

Other Biotechnology & Medical Research

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW